Brief Commentary: Largest Randomized Trial of Biliary Tract Cancer Treatment With Cisplatin Plus Gemcitabine Versus Gemcitabine Alone: An Excellent Opportunity to Evaluate the Prognostic Value of Tumor Marker CA 19-9
- 1 March 2011
- journal article
- Published by Elsevier BV in Clinical Colorectal Cancer
- Vol. 10 (1), 70-71
- https://doi.org/10.3816/ccc.2011.n.012
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract CancerThe New England Journal of Medicine, 2010
- Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study – The UK ABC-01 StudyBritish Journal of Cancer, 2009
- CA 19-9 and Survival in Advanced and Unresectable Pancreatic Adenocarcinoma and CholangiocarcinomaJournal of Gastrointestinal Cancer, 2007
- Prognostic Relevance of Carbohydrate Antigen 19-9 Levels in Patients with Advanced Biliary Tract CancerCancer Epidemiology, Biomarkers & Prevention, 2007
- Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trialsBritish Journal of Cancer, 2007
- Prognostic and Therapeutic Significance of Carbohydrate Antigen 19-9 as Tumor Marker in Patients with Pancreatic CancerOncology, 2006
- Staging, Resectability, and Outcome in 225 Patients With Hilar CholangiocarcinomaAnnals of Surgery, 2001
- A New Strategy for The Application of Ca19-9 in The Differentiation of Pancreaticobiliary Cancer: Analysis Using A Receiver Operating Characteristic CurveThe American Journal of Gastroenterology, 1999
- Colorectal carcinoma antigens detected by hybridoma antibodiesSomatic Cell and Molecular Genetics, 1979